Jorge Correale MDHead of Neuroimmunology, Fleni, Buenos Aires, Argentina
Dr. Jorge Correale graduated with honors from the Faculty of Medicine, University of Buenos Aires, in 1981. Between 1983 and 1988 he completed the residency of Neurology at the Dr. José María Ramos Mejía Hospital, Buenos Aires, and was appointed Chief of Residents. Dr. Correale continued his training as a fellow in Neuroimmunology at the Karolinska Institute in Stockholm, Sweden, between 1989 and 1990. In 1990 he moved to the United States, where he completed a second three-year fellowship in Neuroimmunology at the University of Southern California. In 1993 he was appointed Assistant Professor of Neurology at the University of Southern California, and in 1995 Assistant Professor of Microbiology and Molecular Immunology. In 1997, Dr. Correale returned to Buenos Aires as Head of Neuroimmunology and Demyelinating Diseases at the Neurological Research Institute Fleni, a position he currently holds, where he develops an intense assistance task in the evaluation and follow-up of MS patients. Between 1998 and 2010 he was Associate Professor at the Austral University in Buenos Aires, teaching Clinical Neurophysiology, Physiopathology and Pain Treatment, and Neurology.
He is former Vice President and President of the Argentine Neurological Society, and former President of LACTRIMS. Actually Dr Correale is currently Deputy Chair of the Medical and Scientific Board of MSIF and, and member of the International Advisory Committee on Clinical Trials in MS. Dr. Correale is author of 240 articles published in prestigious journals of Neurology and Immunology, 330 abstracts presented at different international forums in Europe, USA and Canada, 49 chapters in books on Neurology, Multiple Sclerosis and Neuroimmunology, and published as an editor or co-editor 7 books related to Neurology, Multiple Sclerosis and Neuroimmunology.
In the last 5 years, Dr. Correale has received financial compensation for academic presentations, attending advisory boards and assistance for travel to congresses from: Biogen, Merck, Novartis, Roche, Bayer, Sanofi-Genzyme, Gador, Raffo, Bristol Myers Squibb, and Janssen.